Solidus Investment

GB SOFT Co., Ltd. specializes in non-contact measurement solutions for bio-signals, including pulse, blood pressure, oxygen saturation, and heart rate variability. These bio-signals facilitate basic health assessments for daily living and medical environments. By analyzing these signals, the company can provide insights into fatigue, drowsiness, stress levels, and blood sugar. The measurement process is completed in under ten seconds with high accuracy, making it applicable across various sectors, such as automotive, transportation, construction, manufacturing, and well-being. Additionally, GB SOFT offers a safety management platform that enables clients to monitor bio-signals and manage time and attendance, enhancing workplace efficiency and safety through non-contact technology. The company's aim is to create a world where convenient, non-contact bio-signal measurement is accessible to everyone.

Dr.Diary is a company that provides a comprehensive diabetes management application aimed at helping users monitor and manage their condition effectively. Founded in 2017 and based in Seoul, South Korea, the application allows users to track their blood glucose levels, exercise routines, and food intake, while offering insights on how these factors influence their health. In addition to these features, the platform includes medicine intake reminders, monthly health reports, and daily tips on diabetes management. It also facilitates communication with friends and provides personal consultation services with healthcare professionals, enhancing the overall user experience in managing diabetes.

Ubix Therapeutics, Inc. is a research and development company based in Seoul, South Korea, focused on creating anti-cancer drugs through its innovative proteolysis targeting chimera platform technology. This approach employs inhibitor technology to degrade specific target proteins within cells, aiming to enhance therapeutic efficacy for various cancers. By binding to proteins associated with targeted diseases, Ubix Therapeutics seeks to provide effective and life-saving treatments for patients, thereby supporting medical professionals in their efforts to combat cancer.

Mepsgen is a biotechnology research organization that focuses on pharmaceutical services and drug development.

Novelty Nobility Inc. is a private biotechnology company dedicated to researching novel angiogenesis targets to develop antibody-based therapeutics for ophthalmology and oncology. The company has identified a significant target, Stem Cell Factor (SCF) and its receptor c-KIT, which are crucial in the proliferation and survival of hematopoietic stem cells. This discovery aims to address the limitations of existing anti-VEGF treatments, particularly in terms of efficacy and long-term safety. The company's lead candidate, NN2101, a full-human monoclonal antibody, is currently in preclinical development. Novelty Nobility's research is strongly patent-protected in the United States and South Korea, positioning it to provide innovative therapeutic options for diseases associated with abnormal blood vessel growth, such as certain retinal conditions and solid tumors.

MicrobiotiX specializes in developing therapeutics that leverage bacteriophages and the microbiome to address multidrug-resistant infections and autoimmune diseases. The company has created a platform that facilitates the use of safe gastrointestinal microbiota transplants, enabling the formulation of fecal microbiota transplant capsules for oral administration. This innovative approach allows for convenient and cost-effective treatment options for patients, while also focusing on the research and development of bacteriophages. By integrating these technologies, MicrobiotiX aims to improve healthcare outcomes and combat pressing medical challenges.

DAAN Biotherapeutics focuses on developing innovative cancer treatments, particularly for lung cancer. The company conducts research and development in immune-oncology, utilizing advanced strategies such as anticancer immune cell therapy that employs natural killer (NK) cells and T cell receptors. DAAN Biotherapeutics aims to create effective therapies by integrating various treatment modalities, including cell therapies, antibodies, and small molecule inhibitors. Their work involves conducting clinical trials based on independent research infrastructure, with the objective of providing healthcare providers with effective options for treating cancer patients.

Kanaph Therapeutics Inc. is a biotechnology company focused on drug development, from discovery to early-stage clinical trials, primarily targeting oncology and autoimmune diseases. Founded in 2019 and headquartered in Seoul, South Korea, the company specializes in creating next-generation therapeutics, including bi-specific antibodies, Fc-fusions, and small molecules. Its oncology pipeline aims to improve immuno-stimulatory activity within the tumor microenvironment to enhance patient response rates for immuno-oncology treatments. Additionally, Kanaph Therapeutics develops therapeutic solutions for autoimmune conditions, utilizing bispecific Fc-fusions that inhibit pathways associated with complement activation and angiogenesis. The company operates in both Korea and the United States, striving to provide innovative treatments for complex diseases.

Neurophet, Inc. is a neuroscience company based in Seoul, South Korea, founded in 2016. It specializes in developing innovative software solutions for brain stimulation and treatment of neurological disorders. The company's flagship product, Neurophet tES Lab, is a simulation software that calculates and visualizes the effects of brain stimulation by utilizing individual brain structures and specific stimulation conditions. Neurophet employs its proprietary Segengine technology, which can automatically segment brain magnetic resonance images into 107 distinct regions within a minute. This technology aids in predicting and investigating stimulation effects for conditions such as Alzheimer's disease, providing clinicians with a three-dimensional brain model and stimulation parameter guidance. By leveraging deep learning and numerical optimization techniques, Neurophet enables healthcare professionals to focus interventions on targeted regions of the brain, enhancing treatment efficacy for patients with brain diseases.

Onnuri Store sells household goods, beauty, health, and food products.

Dot Mill is a mixed reality content production company.

IMBiologics is a biotechnology company focused on developing immunomodulatory antibody drugs aimed at achieving physiological balance. The company specializes in creating novel treatment options for autoimmune diseases and cancer through its innovative antibody-based biologics. By utilizing unique mechanisms of action to modulate the immune system, IMBiologics enables advancements in cancer treatment and enhances the potential for new therapeutic strategies in the field of modern biomedicine.

Optolane Technologies Inc. is a biotechnology company based in Seongnam, South Korea, founded in 2012. The company specializes in developing portable photo sensor chip-based PCR machines for life science applications. Its diagnostic device offers alternatives for point-of-care testing (POCT) in molecular and immunoassay diagnostics. By integrating optical and thermal control systems, Optolane's semiconductor-based in-vitro diagnostic devices enable real-time and digital PCR, facilitating timely disease diagnosis and enhancing the quality of life for individuals.

Healthbiome is a company that researches and develops microbiome-based treatment.

GB SOFT Co., Ltd. specializes in non-contact measurement solutions for bio-signals, including pulse, blood pressure, oxygen saturation, and heart rate variability. These bio-signals facilitate basic health assessments for daily living and medical environments. By analyzing these signals, the company can provide insights into fatigue, drowsiness, stress levels, and blood sugar. The measurement process is completed in under ten seconds with high accuracy, making it applicable across various sectors, such as automotive, transportation, construction, manufacturing, and well-being. Additionally, GB SOFT offers a safety management platform that enables clients to monitor bio-signals and manage time and attendance, enhancing workplace efficiency and safety through non-contact technology. The company's aim is to create a world where convenient, non-contact bio-signal measurement is accessible to everyone.

M2S specializes in creating digital contents of VR and AR.

Jocoos is a company focused on creating engaging platforms that empower individuals to share their talents and pursue their aspirations. Its flagship product, SURT, is a mobile application designed specifically for artists and musicians, enabling them to showcase their skills and connect with agencies, recording companies, producers, and fans. Additionally, Jocoos has developed cloud-based video technology that facilitates live streaming for various business applications. This technology includes a transcoder and live-streaming capabilities, along with a video editing tool that allows users to incorporate multimedia files, enhancing their ability to produce and share enjoyable live video content. Through these innovations, Jocoos aims to inspire creativity and connection among users.

Pharos iBio Co. is a biotechnology company focused on the development of innovative treatments for rare and intractable diseases. Leveraging a novel drug development platform that incorporates big data and artificial intelligence technology, the company aims to address significant medical needs. Among its product candidates are PHI-101-AML, targeting refractory or relapsed acute myeloid leukemia; PHI-101-OC, designed for patients with platinum-resistant or refractory ovarian cancer; and PHI-101-TNBC, aimed at treating metastatic triple-negative breast cancer. Additionally, the company is advancing several other candidates, including PHI-201, PHI-301, and PHI-501. Through its targeted approach, Pharos iBio seeks to contribute to the advancement of treatment options in oncology.

Himedi, Inc. is a digital health platform based in Seoul, South Korea, founded in 2011. The company connects international patients with medical service providers in South Korea, facilitating access to healthcare services. Himedi offers a hospital reservation service and provides consultations with doctors, while also recommending clinics suited to the patients' needs. Additionally, service managers accompany clients throughout their medical journeys, ensuring a seamless experience. This approach aims to enhance the quality of life for medical tourists by offering tailored healthcare solutions and support during their stay.

Market Designers is a company focused on transforming the brick-and-mortar market by leveraging online innovation to create new business opportunities. The company is developing various housing-related services, including running and cleaning, while also innovating market structures through advanced technology tailored to specific market characteristics. Their on-demand matching platform connects service providers with customers by utilizing algorithms to effectively align consumer needs with available services across sectors such as professional moving, cleaning, mortgage, and education. This approach enhances visibility for service providers and helps them expand their client base.

Orum Therapeutics is a private biotechnology company based in Daejeon, South Korea, founded in 2016. The company specializes in the research and development of therapeutic antibodies through its innovative cell-penetrating antibody platform, Oromab™. This platform is designed to target cytosolic proteins, addressing unmet medical needs in cancer and rare genetic diseases. Orum's unique approach allows for the intracellular delivery of active antibody therapeutics or payloads, enabling the inhibition of drug targets that have been previously considered undruggable by conventional small molecules or antibody therapies. Orum's technology is adaptable to various cell types and intracellular proteins without requiring chemical modifications, aiming to develop effective treatments with improved specificity and reduced toxicity.

MOTIV Intelligence is an advertising technology company that focuses on automating the marketing process. The company utilizes user behavioral data collected from mobile devices to deliver personalized advertisements to website visitors who abandon their shopping carts without making a purchase. By leveraging this data, MOTIV Intelligence aims to enhance engagement and conversion rates for businesses, ensuring that potential customers receive tailored marketing messages that resonate with their interests and behaviors.

Orum Therapeutics is a private biotechnology company based in Daejeon, South Korea, founded in 2016. The company specializes in the research and development of therapeutic antibodies through its innovative cell-penetrating antibody platform, Oromab™. This platform is designed to target cytosolic proteins, addressing unmet medical needs in cancer and rare genetic diseases. Orum's unique approach allows for the intracellular delivery of active antibody therapeutics or payloads, enabling the inhibition of drug targets that have been previously considered undruggable by conventional small molecules or antibody therapies. Orum's technology is adaptable to various cell types and intracellular proteins without requiring chemical modifications, aiming to develop effective treatments with improved specificity and reduced toxicity.

essys is a Manufacturing and sales of automotive IT parts.

Anygen Co., Ltd. is a bio-venture company based in Gwangju and Jeonnam province, established in 2000. It specializes in the development of peptide biomaterials and quality management technologies. The company manufactures a variety of peptide active pharmaceutical ingredients (APIs), including GMP, generic, custom, and catalog peptides. In 2016, Anygen was listed on the KOSDAQ market, bolstered by its proprietary peptide biomaterials and innovative drug development technologies. The company is recognized for supplying high-quality peptide medicinal materials, being the first in Korea to achieve GMP approval. By providing competitively priced peptide drug raw materials, Anygen aims to stabilize market prices and contribute to public health initiatives while expanding its presence in the global market.

Techcross is a manufacturer of ballast water management systems focused on protecting the marine environment. The company develops innovative systems that employ electrolysis technologies to prevent the pollution of ship ballast water from large vessels, including tankers and container ships. By enabling the treatment of invasive marine species contained in ballast water, Techcross plays a crucial role in promoting sustainable maritime practices across various countries.

Purunagun Distribution is a Manufacture and distribution of ice cream with domestic agricultural products.

Cheongwoo Food is a Comprehensive Confectionery.

VitroSys Inc. is a bio-engineering company based in Yeongju, South Korea, established in 2002. The company specializes in the development and manufacturing of a variety of products derived from natural materials, particularly focusing on the cultured roots of Korean mountain ginseng. Their offerings include extracts, beverages, and nano powders made from ginseng, as well as a range of health foods and medicinal materials. VitroSys also operates a research center dedicated to biotechnology and the industrialization of beneficial plant resources, utilizing Good Manufacturing Practices (GMP) and bioreactors to produce functional foods. Additionally, the company provides plant cloning services and engages in research outsourcing and collaborative research initiatives, aiming to create complete plant-based medicines from single cells or tissues.

Genomictree, Inc. is a molecular diagnostics company focused on epigenomic biomarker-based technologies. The company develops innovative solutions aimed at addressing unmet needs within the healthcare market. By leveraging advancements in molecular diagnostics, Genomictree strives to enhance disease detection and management, ultimately improving patient outcomes.

Alteogen Inc. is a biopharmaceutical company founded in 2008 and based in Daejeon, South Korea. The company specializes in developing next-generation biobetters, antibody-drug conjugates, and antibody biosimilars. Its portfolio includes several innovative products, such as ALT-P1, a long-acting human growth hormone currently in Phase IIa clinical trials, and ALT-Q2, a long-acting coagulation factor VII for hemophilia treatment based on NexP technology. Additionally, Alteogen is developing ALT-P7, a targeted treatment for breast and gastric cancer in Phase I trials, and ALT-Q5, an antibody-drug conjugate for ovarian cancer utilizing NexMab technology. The company has established strategic alliances with Kissei Pharmaceutical for Aflibercept, which has completed pre-clinical trials, and with Cristalia for Trastuzumab, currently in Phase II trials for breast cancer. Through these efforts, Alteogen aims to enhance the efficacy and accessibility of biopharmaceuticals.

Novarex Co., Ltd. is a South Korean company specializing in the development and production of health functional foods and raw materials, both domestically and internationally. Founded in 2008 and headquartered in Cheongju, the company offers a diverse range of dietary supplements, including lactic acid bacteria, probiotics, omega-3 products, and vitamins. Novarex also provides health products tailored for specific needs, such as eye health, dietary support, and maternal and children's nutrition. The product formats include tablets, hard capsules, powders, gumi jellies, and stick jellies. Originally known as Health Science Co., Ltd., the company rebranded to Novarex in November 2011.

IDAL SYSTEM is a Smart RPC Management System.

Kookdae F & B is a franchise business.

BioLeaders Corporation is a healthcare company based in Yongin, South Korea, founded in 1999. The company focuses on developing innovative medicines, particularly in the field of oncology, with its flagship product being P53, an anti-cancer drug. BioLeaders is advancing several pipeline products, including BLS-H01, currently in phase 3 clinical trials for cervical cancer, and BLS-M07, which has completed phase 2b trials for the same condition. Additionally, the company is working on BLS-M22 for the treatment of Duchenne muscular dystrophy and BLC-H03, a vaccine adjuvant. Beyond pharmaceuticals, BioLeaders also offers health functional foods, raw materials, and functional cosmetic ingredients, positioning itself as a comprehensive provider in the healthcare sector.

Maniker F&G Co., Ltd. is a South Korean company that specializes in the production, processing, and sale of frozen, chilled, and retorted food products. Established in 1993 and headquartered in Yongin, the company offers a variety of chicken and beef items, including Ginseng chicken stew, Mung bean chicken stew, Premium Samgyetang, boneless chicken tenders, and popcorn chicken. Maniker F&G is committed to delivering safe and delicious food products through advanced meat processing technology. The company also exports its offerings to the United States, aiming to enhance customer health and convenience through continuous innovation and improvement.